SECOBARBITAL INTERNATIONAL CONTROLS TRANSFER FROM SCHEDULE III TO II
SECOBARBITAL INTERNATIONAL CONTROLS TRANSFER FROM SCHEDULE III TO II is being proposed by the U.S. government, FDA announced in an Oct. 27 Federal Register notice. The agency, noting that secobarbital has been in Schedule II in the U.S. since 1972, stated that "the time has come for the international community to consider similiar actions." FDA said the U.S. government "has informed the Secretary-General of the United Nations" that it believes the drug should be rescheduled under the Controlled Substances Act. FDA cited a September 1985 secobarbital trafficking report which concluded that "substantial quantities of secobarbital are being diverted from international commerce for illicit purposes." According to the report, secobarbital is being substituted for methaqualone in illicit pharmaceutical products which often originate from Mexican or European sources. Large amounts of these secobarbital products have been seized in Africa and in the Middle East, the notice said. The agency asserted that present international Schedule III controls are "inadequate to address the rapidly rising levels of diversion." FDA said the added controls of Schedule II would enable governments to "scrutinize import requests prior to shipment, and determine whether the products serve legitimate needs." Schedule II products require separate import or export authorization. Five other barbiturate-type sedative and/or hypnotic drug substances are also being recommended for rescheduling by the World Health Organization. Allobarbital, butobarbital, secbutabarbital, and vinylbital are recommended for Schedule IV while butalbital is recommended for inclusion in Schedule III. FDA said in a separate Oct. 27 Federal Register notice that the drugs are or are "likely to be abused so as to constitute a public health and social problem warranting placing [them] under international control."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth